首页> 外文期刊>Annals of surgical oncology >Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ
【24h】

Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ

机译:12-基因DCIS评分测定的临床实用性:对导管癌原位患者的放射疗法建议的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Objective. The aim of this study was to determine the impact of the results of the 12-gene DCIS Score assay on (i) radiotherapy recommendations for patients with pure ductal carcinoma in situ (DCIS) following breast-conserving surgery (BCS), and (ii) patient decisional conflict and state anxiety. Methods. Thirteen sites across the US enrolled patients (March 2014-August 2015) with pure DCIS undergoing BCS. Prospectively collected data included clinicopatho-logic factors, physician estimates of local recurrence risk, DCIS Score results, and pre-/post-assay radiotherapy recommendations for each patient made by a surgeon and a radiation oncologist. Patients completed pre-/post-assay decisional conflict scale and state-trait anxiety inventory instruments. Results. The analysis cohort included 127 patients: median age 60 years, 80 % postmenopausal, median size 8 mm (39 % ≤5 mm), 70 % grade 1/2, 88 % estrogen receptorpositive, 75 % progesterone receptor-positive, 54 % with comedo necrosis, and 18 % multifocal. Sixty-six percent of patients had low DCIS Score results, 20 % had intermediate DCIS Score results, and 14 % had high DCIS Score results; the median result was 21 (range 0-84). Pre-assay, surgeons and radiation oncologists recommended radiotherapy for 70.9 and 72.4 % of patients, respectively. Post-assay, 26.4 % of overall recommendations changed, including 30.7 and 22.0 % of recommendations by surgeons and radiation oncologists, respectively. Among patients with confirmed completed questionnaires (n = 32), decision conflict (p = 0.004) and state anxiety (p = 0.042) decreased significantly from pre- to post-assay. Conclusions. Individualized risk estimates from the DCIS Score assay provide valuable information to physicians and patients. Post-assay, in response to DCIS Score results, surgeons changed treatment recommendations more often than radiation oncologists. Further investigation is needed to better understand how such treatment changes may affect clinical outcomes.
机译:客观的。本研究的目的是确定12-基因DCIS评估结果对(i)放疗患者对哺乳期外科(BCS)之后的纯导管癌的患者的放疗建议的影响(I),(II )患者毁灭性冲突和国家焦虑。方法。联合美国患者的十三个网站(2015年3月至2015年8月),纯DCIS接受了BCS。潜在收集的数据包括临床疗法逻辑因素,医生估算局部复发风险,DCIS评分结果和对外科医生和放射肿瘤学家制成的每位患者的患者的预期/后测定放射治疗建议。患者完成了预期/后期后判决冲突规模和国家特质焦虑库存工具。结果。分析队列包括127名患者:中位年龄60岁,后期绝经后,中位数8毫米(39%≤5mm),70%级1/2,88%雌激素受体,75%孕酮受体阳性,54% Comedo坏死和18%的多焦点。六十六名患者具有低DCIS评分结果,20%具有中间DCIS评分结果,14%具有高DCIS得分结果;中值结果为21(范围0-84)。预先测定,外科医生和放射肿瘤学家分别推荐70.9和72.4%的患者的放疗。后测定后,26.4%的总体建议改变,包括外科医生和放射肿瘤学家的30.7%和22.0%。在确认完成的问卷(N = 32)的患者中,从前调后,决策冲突(P = 0.004)和状态焦虑(p = 0.042)显着降低。结论。来自DCIS评分测定的个性化风险估计为医生和患者提供了有价值的信息。检测后,响应DCIS得分结果,外科医生比放射肿瘤学家更频繁地改变了治疗建议。需要进一步调查以更好地了解这种治疗如何变化可能影响临床结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号